The use of an anti-inflammatory supplement in patients with chronic kidney disease

Abstract

Chronic kidney disease (CKD) is characterized by a continuous reduction in kidney function, increased inflammation, and reduced antioxidant capacity. The objective of this study was to assess the effects of a herbal supplement on systemic inflammation and antioxidant status in non-dialysis CKD patients. Sixteen patients with CKD (56.0±16.0 yrs, 171.4±11.9 cm, 99.3±20.2 kg) were randomly chosen to receive a herbal supplement composed of Curcuma longa and Boswellia serrata, or placebo. Plasma levels of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), glutathione peroxidase (GPx), and serum C-reactive protein (CRP) were measured at baseline and 8 weeks. Baseline data demonstrated elevated inflammation and low antioxidant levels. A significant time effect (p=0.03) and time x compliance interaction effect (p=0.04) were observed for IL-6. No significant differences were observed for any other variables. This study demonstrates that mild and moderate CKD is associated with chronic inflammation and low antioxidant activity. Systemic inflammation and impaired antioxidant status may be greater in CKD populations with multiple comorbidities. Curcumin and Boswellia serrata are safe and tolerable and helped to improve the levels of an inflammatory cytokine.

The effects of curcumin‐containing supplements on biomarkers of inflammation and oxidative stress: A systematic review and meta‐analysis of randomized controlled trials

“…Mohammadi, Kayedpoor, Karimzadeh‐Bardei, and Nabiuni () found out that anti‐inflammatory and antioxidative impacts of curcumin in patients with polycystic ovary syndrome is related to its function of inhibiting the gene expression of tumor necrosis factor‐α (TNF‐α), and reducing the circulating levels of CRP and interleukin‐6 (IL‐6). In addition, anti‐inflammatory effects of curcumin in patients diagnosed with metabolic syndrome have been demonstrated by others (Moreillon et al, ; Panahi et al, ). In a trial conducted on patients with tropical pancreatitis, curcumin ingestion at a dosage of 500 mg/day for 6 weeks significantly reduced malonyldialdehyde (MDA) concentrations and led to a significant increase in glutathione levels (Durgaprasad, Pai, Vasanthkumar, Alvres, & Namitha, ).…”

Protective effects of curcumin on acute gentamicin-induced nephrotoxicity in rats

“…Third, these natural antioxidants still have the problems related to nonspecificity, impurity, or potential side effect undetected yet. In fact, in a randomed clinical trial, a herbal supplement composed of Curcuma longa and Boswellia serrata was given to patients with chronic kidney disease, the data shown that the herb which helped to improve the levels of antioxidant activity is safe and tolerable for these patients (Moreillon et al 2013). …”

Curcumin attenuates cyclosporine A-induced renal fibrosis by inhibiting hypermethylation of the klotho promoter

“…The in vivo and in vitro results display significant levels of expression of various ECM components, such as PAI-1, α-SMA and Col I, all of which may be the downstream biological events of the TGF-β signaling pathway. Previous studies have indicated that curcumin influences cytokine secretion and inflammation in CKD patients (30,31); the current data indicated that curcumin exerts nephroprotective effects, at least partially, via anti-TGF-β signaling.…”